CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead
CorMedix (NASDAQ:CRMD) used its 2026 Analyst and Investor Day to outline its shift from a single-product renal-focused company to what management described as a diversified, cash-flow-generating...